©DANIEL ROUSSELOT/Sanofi

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Originally published on Sanofi.com.

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with BARDA.

COVID-19 belongs to a family of coronaviruses that can cause respiratory disease. In late 2002, the SARS (severe acute respiratory syndrome) coronavirus emerged and then largely disappeared by 2004. Sanofi plans to further investigate an advanced pre-clinical SARS vaccine candidate that could protect against COVID-19.

“Addressing a global health threat such as this newest coronavirus is going to take a collaborative effort, which is why we are working with BARDA to quickly advance a potential vaccine candidate,” said David Loew, Global Head of Vaccines at Sanofi. “While we are lending our expertise where possible, we believe the collaboration with BARDA may provide the most meaningful results in protecting the public from this latest outbreak.”

Sanofi to utilize innovative recombinant technology platform

Sanofi will use its recombinant DNA platform to produce a 2019 novel coronavirus vaccine candidate.  The recombinant technology produces an exact genetic match to proteins found on the surface of the virus. The DNA sequence encoding this antigen will be combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product, and used to rapidly produce large quantities of the coronavirus antigen which will be formulated to stimulate the immune system to protect against the virus.

        “Emerging global health threats like the 2019 novel coronavirus require a rapid response,” said BARDA Director Rick A. Bright, Ph.D.  “By expanding our partnership               with Sanofi Pasteur and leveraging a licensed recombinant vaccine platform, we hope to speed development of a vaccine candidate to protect against a new virus.”

Sanofi uniquely positioned in search for a coronavirus vaccine

In non-clinical studies, the SARS vaccine candidate was immunogenic and afforded partial protection as assessed in animal challenge models. This development work by Protein Sciences (acquired by Sanofi in 2017) provides a head start in expediting a COVID-19 vaccine. Additionally, since there is a licensed vaccine based on this platform this will allow for research and materials to be produced relatively quickly for clinical testing. Sanofi’s platform also has the potential to manufacture large quantities of the vaccine candidate.

Sanofi’s long-standing commitment to protecting public health

This agreement with BARDA marks another milestone in Sanofi’s ongoing contributions to help fight public health threats.  Sanofi continues to actively explore potential opportunities where the company’s deep vaccine experience and innovative technologies may contribute to addressing the coronavirus public health situation, including sharing Sanofi’s vaccine research and development experience with the Coalition for Epidemic Preparedness Innovations.

In December 2019, Sanofi also entered into an agreement with BARDA to establish state of the art facilities in the U.S. for the sustainable production of an adjuvanted recombinant vaccine for use in the event of an influenza pandemic and based on the same technology platform that will be used for the COVID-19 program.

Latest News

ICE, whistleblower hysterectomies, COVID

ICE Whistleblower Alleges Unnamed Doctor Performing Hysterectomies, Denying COVID Tests to Detainees

At Immigration and Customs Enforcement (ICE) detainment centers, undocumented detainees are being subjected to “questionable” hysterectomies and are being denied COVID tests, according to a whistleblower. Dawn Wooten, a nurse who worked at the Irwin County Detention Center in Ocilla, GA recently filed a whistleblower complaint alleging medical neglect. A…

nielsen

Launching Nielsen Compass: A World-Leading and Powerful Campaign Outcomes Database

Originally published on nielsen.com. ADVERTISERS, AGENCIES AND PUBLISHERS TO LEVERAGE INSIGHTS FROM WORLD LEADING, OUTCOME MEASUREMENT DATASET TO MAKE DATA-DRIVEN DECISIONS, OPTIMIZE BUDGETS AND PREDICT SALES ROI Nielsen (NYSE: NLSN) today announced that it is launching Nielsen Compass, a powerful, world leading database that leverages the company’s global scale to…

Mastercard Outlines Sustainability Goals

Originally published on mastercardcontentexchange.com. Now is the time to work together to create a better world. If there’s a silver lining to this tumultuous time we’re living through, it’s that the pandemic has shown clearly just how interconnected we all are. The actions of an individual — whether by taking…

Cigna

Cigna Launches Evernorth to Accelerate Delivery of Innovative and Flexible Health Services and Flexible

Originally published on Cigna.com  Cigna Corporation (NYSE: CI) announces the launch of Evernorth, a new brand for its growing, high-performing health services portfolio. Evernorth will accelerate delivery of innovative and flexible solutions to meet the diverse needs of health plans, employers, and government organizations. Experience the interactive Multichannel News Release…

AT&T Works with Year Up to Close the Opportunity Divide

Originally published on ATT.com Young people are facing strong headwinds as they pursue career success in today’s economy. But there are bright spots. Now and in coming weeks, we’re highlighting individuals working hard to succeed despite their challenges. We’re raising awareness of what’s possible to inspire and encourage others. It’s…

ADP® DataCloud Wins 2020 Artificial Intelligence (AI) Breakthrough Award

Originally published on ADP.com Powerful workforce analytics solution honored for innovative application of predictive analytics and machine learning Recognized as a leading company in the global AI market today, ADP was selected as a winner in the 2020 AI Breakthrough Awards for its innovative workforce analytics solution, ADP® DataCloud. Named as winner for…